| LncRNA Information | ||||||
|---|---|---|---|---|---|---|
| ID | EL0260 | Name | C5orf66-AS1 | Aliases | CTC-276P9.1; Epist | |
| Species | Homo sapiens | Chromosome | 5 | Start site | 135038831 | |
| End site | 135040047 | Chain | minus | Exon NO. | 2 | |
| Assembly | Ensembl Release 89 | Class | lincRNA | NCBI accession | NR_105050, NR_105049 | |
| Ensembl | ENSG00000249082 | Sequence | ||||
| Disease | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source | ||
| esophageal squamous cell carcinoma | microarray, qPCR etc. | cell lines (KYSE510, KYSE450, KYSE150, KYSE30, EC109, TE-1) | down-regulated | expression | We identified a novel nuclear-retained lncRNA, named Epist, which is generally highly expressed in esophagus, and which is down-regulated during ESCC progression. Epist over-expression and knockdown studies further suggest that Epist inhibits the metastasis, acting as a tumor suppressor in ESCC. Collectively | 26158411 | Lnc2Cancer | ||
| bladder cancer | microarray, qPCR, knockdown etc. | bladder cancer tissue | down-regulated | N/A | Four lncRNAs were selected for further confirmation of microarray results using qPCR. These lncRNAs were among the most downregulated or upregulated lncRNAs. Data analysis showed that KRT19P3 was upregulated and TNXA, CTA-134P22.2 and CTC-276P9.1 were downregulated in bladder cancer samples compared with matched normal tissues.these deregulated lncRNAs play a key or partial role in the development and/or progression of bladder cancer. | 24944692 | Lnc2Cancer | ||